WO2011137459A1 - Formes galéniques de l'élinogrel et leurs méthodes d'administration injectables - Google Patents

Formes galéniques de l'élinogrel et leurs méthodes d'administration injectables Download PDF

Info

Publication number
WO2011137459A1
WO2011137459A1 PCT/US2011/034861 US2011034861W WO2011137459A1 WO 2011137459 A1 WO2011137459 A1 WO 2011137459A1 US 2011034861 W US2011034861 W US 2011034861W WO 2011137459 A1 WO2011137459 A1 WO 2011137459A1
Authority
WO
WIPO (PCT)
Prior art keywords
elinogrel
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
solution
Prior art date
Application number
PCT/US2011/034861
Other languages
English (en)
Inventor
Hui Li
Juan Wang
Joe Lambing
Harry Tiemessen
Original Assignee
Portola Pharmaceuticals, Inc.
Novartis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals, Inc., Novartis Pharma Ag filed Critical Portola Pharmaceuticals, Inc.
Priority to US13/695,428 priority Critical patent/US20130131089A1/en
Publication of WO2011137459A1 publication Critical patent/WO2011137459A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • the present invention relates to compositions for the delivery of pharmacologically active agents by injection and to methods of treating and/or preventing disease in mammals, particularly humans, by administering a pharmacologically active agent in accordance with the invention.
  • Thrombotic complications are a major cause of death in the industrialized world. Examples of these complications include acute coronary syndrome (ACS), acute myocardial infarction, unstable angina, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, preeclampsia/eclampsia, deep venous thrombosis, embolism, disseminated intravascular coagulation and thrombotic cytopenic purpura.
  • ACS acute coronary syndrome
  • acute myocardial infarction unstable angina
  • chronic stable angina chronic stable angina
  • transient ischemic attacks strokes
  • peripheral vascular disease preeclampsia/eclampsia
  • embolism preeclampsia/eclampsia
  • embolism disseminated intravascular coagulation and thrombotic cytopenic purpura.
  • Thrombotic and restenotic complications also occur following invasive procedures, e.g., angioplasty, carotid endarterectomy, post CABG (coronary artery bypass graft) surgery, vascular graft surgery, stent placements and insertion of endovascular devices and prostheses, and hypercoagulable states related to genetic predisposition or cancers. It is generally thought that platelet aggregates play a critical role in these events. Blood platelets, which normally circulate freely in the vasculature, become activated and aggregate to form a thrombus from disturbed blood flow caused by ruptured atherosclerotic lesions or by invasive treatments such as angioplasty, resulting in vascular occlusion. Platelet activation can be initiated by a variety of agents, e.g., exposed subendothelial matrix molecules such as collagen, or by thrombin which is formed in the coagulation cascade.
  • agents e.g., exposed subendothelial matrix molecules such as collagen, or by
  • Elinogrel As its potassium salt, Elinogrel has a molecular weight of 562.04 (free acid 523.95). Its pKa is about 3.3 with a logP of about 2.5 and logD (pH 7.4) of about -1.6. Formulation of Elinogrel has proven difficult due, at least in part, to the poor aqueous solubility of the free acid form which is ⁇ 0.1 mg/ml (i.e. practically insoluble) at pH 1.0 -7.4. Techniques have been disclosed for preparing sustained (or controlled) release pharmaceutical formulations of Elinogrel (see e.g. U.S. Patent Application Serial No. 12/618,511 filed November 13, 2009.
  • thermodynamic solubility of a compound can be lower than the concentration of the compound after reconstitution from a lyophilized formulation.
  • Reconstitution of the previous lyophilized intravenous (IV) formulations and storage could potentially cause precipitation especially if seed crystals exist or form in solution. Therefore, there exists a continuing need for further improvement in injectable preparations which accommodate higher clinical doses and provide still greater unit dose of Elinogrel, and other weakly acidic drugs, or their pharmaceutically acceptable salts. Accordingly, there is a significant need for highly concentrated liquid formulations of these compounds, e.g. up to about 15 mg/ml which avoid problems of instability due to the formation of particulates or other components which make further processing difficult.
  • the present invention is directed to pharmaceutical compositions administrable by injection which, unexpectedly, greatly enhances the unit dose of a weakly acidic drug compound or a pharmaceutically acceptable salt thereof, with poor aqueous solubility, such as Elinogrel.
  • the invention provides a stable, highly concentrated liquid pharmaceutical composition comprising at least about 3 mg/mL Elinogrel, or a pharmaceutically acceptable salt thereof.
  • the invention provides a lyophilized pharmaceutical composition which comprises at least about 3 mg/ml Elinogrel, or a pharmaceutically acceptable salt thereof after reconstitution in solution.
  • the invention is directed to a dosage form comprising: a liquid or lyophilized pharmaceutical composition comprising: a) at least about 3 mg/ml Elinogrel or a pharmaceutically acceptable salt thereof, and b) at least one pharmaceutically acceptable excipient.
  • the invention is directed to a method of treating or preventing a thrombotic conditions in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a liquid pharmaceutical composition comprising: a) at least about 3 mg/ml Elinogrel or a pharmaceutically acceptable salt thereof, and b) at least one pharmaceutically acceptable excipient.
  • the present invention provides a method to aid in and keeping Elinogrel, or its pharmaceutically acceptable salts thereof, miscible and inhibiting
  • solubilizer or crystallization inhibitor is sodium sulfobutyl ether ⁇ -cyclodextrin (SBE-beta-CD, CAPTISOL ), or pharmaceutically acceptable salts thereof or combinations thereof.
  • the present invention provides a method of producing a lyophilized pharmaceutical composition comprising at least about 3 mg/mL Elinogrel post reconstitution, or a pharmaceutically acceptable salt; by contacting a) Elinogrel or a pharmaceutically acceptable salt thereof, with b) at least one pharmaceutically acceptable excipient.
  • Another aspect of the present invention relates to a method for producing the liquid or lyophilized formulation.
  • Figure 1 shows the kinetic solubility of Forms B & C of Elinogrel potassium in a liquid formulation containing mannitol and glycine buffer.
  • Figure 2 shows the thermodynamic solubility of Elinogrel as a free acid and as a potassium salt at different pH (adjusting pH with either NaOH or HC1) at 37°C.
  • formulation and “composition” are used interchangeably and refer to a mixture of two or more compounds, elements, or molecules. In some aspects the terms “formulation” and “composition” may be used to refer to a mixture of one or more active agents with a carrier or other excipients.
  • pharmaceutical formulation refer to a pharmaceutical composition comprising the active ingredient and optionally further excipients to make it suitable to apply to a patient and is usually a finished drug product. The term “pharmaceutical formulation” and “pharmaceutical composition” may be interchangeably used herein depending on the context of these terms.
  • therapeutic agent used interchangeably herein to refer to a substance having a pharmaceutical, pharmacological, psychosomatic, or therapeutic effect.
  • Suitable agents for use in the present invention include, without limitation, compounds which have the formula (I):
  • R 1 is selected from the group consisting of H, halogen, -OH, -Ci_i 0 -alkyl and Ci_ 6 -alkylamino; and X is selected from the group consisting of: F and I, or a pharmaceutically acceptable salt thereof; and combinations thereof.
  • the active agent is in a salt form such as that shown below, where the symbol M represents a suitable counterion, such as an alkali metal.
  • the active agent is [4-(6-fluoro-7-methylamino-2,4- dioxo- 1 ,4-dihydro-2H-quinazolin-3-yl)-phenyl] -5 -chloro-thiophen-2-yl- sulfonylurea, (also referred to as 5-chloro-N-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-l,2-dihydro-2H- quinazolin-3(4H)-yl)-phenylcarbamoyl)-thiophene-2-sulfonamide or Elinogrel), according to the structural formulae below:
  • the present invention is applicable not only to [4-(6-fluoro-7-methylamino-2,4- dioxo- 1 ,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, but also to other weakly acidic drugs with poor aqueous solubility.
  • the term "preventing” refers to the prophylactic treatment of a patient in need thereof.
  • the prophylactic treatment can be accomplished by providing an appropriate dose of a therapeutic agent to a subject at risk of suffering from an ailment, thereby substantially averting onset of the ailment.
  • treating refers to providing an appropriate dose of a therapeutic agent to a subject suffering from an ailment.
  • condition refers to a disease state for which the compounds, compositions and methods of the present invention are being used against.
  • ADP -mediated disease or condition and the like refers to a disease or condition characterized by less than or greater than normal, ADP activity.
  • An ADP -mediated disease or condition is one in which modulation of ADP results in some effect on the underlying condition or disease (e.g., a ADP inhibitor or antagonist results in some improvement in patient well-being in at least some patients).
  • subject refers to a mammal that may benefit from the
  • a subject is a human.
  • an "effective amount” or a “therapeutically effective amount” of a drug refers to a non-toxic, but sufficient amount of the drug, to achieve therapeutic results in treating a condition for which the drug is known to be effective, especially a thrombotic condition. It is understood that various biological factors may affect the ability of a substance to perform its intended task. Therefore, an "effective amount” or a “therapeutically effective amount” may be dependent in some instances on such biological factors. Further, while the achievement of therapeutic effects may be measured by a physician or other qualified medical personnel using evaluations known in the art, it is recognized that individual variation and response to treatments may make the achievement of therapeutic effects a somewhat subjective decision. The determination of an effective amount is well within the ordinary skill in the art of pharmaceutical sciences and medicine. See, for example, Meiner and Tonascia, "Clinical Trials: Design, Conduct, and Analysis,” Monographs in
  • pharmaceutically acceptable carrier or “excipient” may be used interchangeably, and refer to any inert and pharmaceutically acceptable material that has substantially no biological activity, and makes up a substantial part of the formulation.
  • a “stable" formulation is one in which the compounds therein essentially retain its physical and chemical stability and integrity upon storage. Stability can be measured at a selected temperature for a selected time period. For rapid screening, the formulation may be kept at 40°C for 2 weeks to 1 month, at which time stability is measured. Where the formulation is to be stored at 2-8 °C, generally the formulation should be stable at 30 °C or 40 °C for at least 1 month and/or stable at 2-8 °C for at least 2 years. Where the formulation is to be stored at 30 °C, generally the formulation should be stable for at least 2 years at 30 °C and/or stable at 40 °C for at least 6 months. For example, the extent of precipitation during storage can be used as an indicator of stability. Thus, a “stable" formulation may be one wherein less than about 10% and preferably less than about 5% of the compound precipitates from the formulation.
  • a "reconstituted" formulation is one which has been prepared by dissolving a lyophilized formulation in a diluent such that the compound throughout.
  • the reconstituted formulation is suitable for administration (e.g. parenteral administration) to a patient to be treated with the compound of interest and, in certain embodiments of the invention, may be one which is suitable for subcutaneous administration.
  • An "isotonic" formulation is one which has essentially the same osmotic pressure as human blood. Isotonic formulations will generally have an osmotic pressure from about 250 to 350 mOsm.
  • the term “hypotonic” describes a formulation with an osmotic pressure below that of human blood.
  • the term “hypertonic” is used to describe a formulation with an osmotic pressure above that of human blood. Isotonicity can be measured using a vapor pressure or ice-freezing type osmometer, for example.
  • the formulations of the present invention are hypertonic as a result of the addition of salt and/or buffer.
  • the term “substantially” refers to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result.
  • an object that is “substantially” enclosed would mean that the object is either completely enclosed or nearly completely enclosed.
  • the exact allowable degree of deviation from absolute completeness may in some cases depend on the specific context. However, generally speaking the nearness of completion will be so as to have the same overall result as if absolute and total completion were obtained.
  • the use of “substantially” is equally applicable when used in a negative connotation to refer to the complete or near complete lack of an action, characteristic, property, state, structure, item, or result.
  • compositions that is "substantially free of particles would either completely lack particles, or so nearly completely lack particles that the effect would be the same as if it completely lacked particles.
  • a composition that is "substantially free of an ingredient or element may still actually contain such item as long as there is no measurable effect thereof.
  • administering refers to the manner in which an active agent is presented to a subject. While much of the disclosure is focused on injectable administration, administration can be accomplished by other various art-known routes that use liquid or lyophilized formulations such as transdermal, inhalation,
  • injectable administration represents any method of administration in which an active agent can be administered through injecting the liquid dosage form.
  • Such liquid or lyophilized dosage forms are traditionally intended to immediately release and or deliver the active agent in the bloodstream.
  • Examples of injection include intravenous (bolus and/or infusion), perivascular, subcutaneous, intramuscular, parenteral or intraperitoneal, etc.
  • injectable dosage form refers to a formulation that is prepared for administration to a subject through an injectable route of administration.
  • liquid or lyophilized dosage forms include without limitation, solutions, suspensions, solutions and solution pre-concentrates, emulsions and emulsion pre-concentrates, etc.
  • the dosage forms of the present invention may be unit dosage forms wherein the dosage form is intended to deliver one therapeutic dose per administration.
  • the invention provides a liquid pharmaceutical composition comprising: a) at least about 3 mg/mL Elinogrel or a pharmaceutically acceptable salt thereof, and b) at least one pharmaceutically acceptable excipient.
  • the invention provides a lyophilized pharmaceutical composition comprising at least about 3 mg/ml Elinogrel, or a pharmaceutically acceptable salt thereof after reconstitution in solution.
  • the invention provides a method of treating or preventing a thrombotic condition in a mammal in need thereof, which method comprises intravenous administering to said mammal an effective amount of a liquid pharmaceutical composition comprising at least about 3 mg/ml Elinogrel.
  • the invention provides a method of producing a liquid pharmaceutical composition comprising at least about 3 mg/ml Elinogrel, or a pharmaceutically acceptable salt thereof; by contacting a) Elinogrel or a pharmaceutically acceptable salt thereof in solution, with b) at least one pharmaceutically acceptable excipient.
  • the invention provides a method of producing a lyophilized pharmaceutical composition comprising at least about 3 mg/ml Elinogrel, or a pharmaceutically acceptable salt thereof after reconstitution; comprising a) forming a solution comprising at least about 3 mg/ml Elinogrel in an aqueous solvent, optionally a co-solvent and a bulking agent and (b) lyophilizing said solution to form a lyophilized pharmaceutical composition.
  • composition provides a desired dose for the active agent under physiological conditions.
  • Active Agents
  • the active agents of the present invention are selected from the class of compounds in the dihydroquinazolinylphenyl thiophenyl sulfonylurea family and are useful in the treatment of conditions such as thrombosis.
  • suitable dihydroquinazolinylphenyl thiophenyl sulfonylurea compounds for use in the present invention have the formula (I):
  • R 1 is selected from the group consisting of H, halogen, -OH, -Ci_io-alkyl and Ci_6-alkylamino;
  • X is selected from the group consisting of: F and I.
  • the agent is [4-(6-fluoro-7-methylamino-2,4-dioxo-l,4-dihydro- 2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, in all suitable forms.
  • the invention provides a liquid or lyophilized composition, wherein the active agent is [4-(6-fluoro-7-methylamino-2,4-dioxo- 1 ,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5- chloro-thiophen-2-yl-sulfonylurea potassium or sodium salt.
  • the active agents of the present invention are a poorly soluble weak acid compound in its salt form that has aqueous solubility of less than 0.1 mg/ml at pH 1.0 -7.4 at a temperature of about 37 °C having an ionized form and an un-ionized form.
  • the aqueous solubility increases at a higher pH (e.g. > 1 mg/ml at pH 8 or above).
  • the active agent is initially present at least partly in an ionized form. In certain other instances, the active agent is initially present in an un-ionized form.
  • the excipients of the compositions described herein helps to increase the solubility of the active as pH increases up to pH 10 in a hydrated media. In another embodiment, the excipient of the compositions described herein helps to maintain substantially all of the active agent in its dissolved ionized form in the formulation when it is in a hydrated media.
  • the active agents of the present invention are any weakly acidic drug, or a pharmaceutically acceptable salt thereof with poor aqueous solubility.
  • the term "active agent” includes all pharmaceutically acceptable forms of the active agent being described.
  • the active agent can be in a isomeric mixture, a solid complex bound to an ion exchange resin, or the like.
  • the active agent can be in a solvated form.
  • active agent is also intended to include all pharmaceutically acceptable salts, derivatives, and analogs of the active agent being described, as well as combinations thereof.
  • the pharmaceutically acceptable salts of the active agent include, without limitation, the sodium, potassium, calcium, magnesium, ammonium, tromethamine, L-lysine, L-arginine, N-ethylglucamine, N- methylglucamine and salt forms thereof, as well as combinations thereof and the like.
  • Any form of the active agent is suitable for use in the compositions of the present invention, e.g., a pharmaceutically acceptable salt of the active agent, a free acid of the active agent, or a mixture thereof.
  • the invention provides a liquid or lyophilized composition, wherein the active agent is [4-(6-fluoro-7-methylamino-2,4-dioxo-l,4-dihydro- 2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea potassium salt having a crystalline solid form A or B or [4-(6-fluoro-7-methylamino-2,4-dioxo-l,4-dihydro-2H- quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea sodium salt as described in US- 2007-0123547-A1.
  • the invention provides a liquid or lyophilized composition, wherein the active agent is [4-(6-fluoro-7-methylamino-2,4-dioxo-l,4-dihydro- 2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea sodium salt having a crystalline solid form A or B as described in US-2009-0042916-A1.
  • the active agent initially can be in any suitable form.
  • the active agent can initially be in the form of an amorphous solid, a crystal, a granule, or a pellet.
  • the invention provides a liquid or lyophilized pharmaceutical composition comprising: a) at least about 3 mg/mL Elinogrel or a
  • the liquid pharmaceutical formulation comprises about 4 to about 25 mg/ml Elinogrel, or a pharmaceutically acceptable salt thereof.
  • the liquid or lyophilized pharmaceutical formulation comprises about 15 to 23 mg/ml Elinogrel, or a pharmaceutically acceptable salt thereof.
  • the liquid or lyophilized pharmaceutical formulation comprises about 17 mg/ml Elinogrel, or a pharmaceutically acceptable salt thereof.
  • the liquid or lyophilized pharmaceutical formulation comprises up to about 15 mg/ml Elinogrel free acid, or a pharmaceutically acceptable salt thereof.
  • the liquid or lyophilized pharmaceutical formulation comprises about 10 to about 15 mg/ml Elinogrel free acid, or a pharmaceutically acceptable salt thereof. In one embodiment, the formulation comprises about 8 to about 20 mg per ml Elinogrel, sodium salt.
  • the invention provides a liquid or lyophilized injectable dosage form comprising: a) at least about 3 mg/ml Elinogrel or a pharmaceutically acceptable salt thereof, and b) at least one pharmaceutically acceptable excipient.
  • the invention provides a liquid or lyophilized injectable dosage form comprising Elinogrel or a pharmaceutically acceptable salt thereof in a unit dosage of from between aboutlO and 150 mg.
  • the invention provides a liquid or lyophilized injectable dosage form comprising Elinogrel or a pharmaceutically acceptable salt thereof in a unit dosage of about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 or 120 mg.
  • the invention provides a liquid or lyophilized injectable dosage form produced from the free acid of Elinogrel. In another group of embodiments, the invention provides a liquid or lyophilized injectable dosage form wherein the Elinogrel is the potassium salt of Elinogrel. In another group of embodiments, the invention provides a liquid or lyophilized dosage form wherein the Elinogrel is the sodium salt of Elinogrel.
  • the liquid or lyophilized formulation comprises an excipient.
  • the excipient of the present invention is a solubilizer.
  • the term "solubilizer” refers to salts, ions, carbohydrates, surfactants, complexation agent, polymers and other compounds which, when present in solution, decrease the crystallization of Elinogrel.
  • complexation agent include, but are not limited to sodium sulfobutyl ether ⁇ -cyclodextrin and hydroxypropyl ⁇ - cyclodextrin, and pharmaceutically acceptable salts thereof and combinations thereof.
  • the excipient is present in an amount of about 1% to about 10% by weight. In another group of embodiments, the excipient is present in an amount of about 4% by weight.
  • the formulations of the present invention can be for instance in form of an aqueous solutions.
  • aqueous solutions is meant a solution with the active ingredient and optional pharmaceutical excipients are dissolved using water as the principal solvent.
  • the water may be buffered to stabilize the pH with a suitable buffer such as e.g. a phosphate buffer, acetate, citrate, lactate, glycine, tris, sodium bicarbonate, maleate buffer.
  • the buffer is preferably present in suitable amount to adjust the pH to the desired value, e.g. in a concentration of 1 mM to 50 mM.
  • the "aqueous solution” may further contain a water-miscible organic solvent or solvents.
  • Suitable solvents are those water- miscible solvents commonly used in the art, for example propyleneglycol, polyethyleneglycol 300, polyethyleneglycol 400, glycerol, tween 20, tween 80 and ethanol.
  • a formulation of the invention may comprise an isotonic agent which has the effect of rendering the osmotic pressure of the formulation the same as that of body fluid.
  • the isotonic agent may be selected from any of those commonly used in the art, e.g. sucrose, mannitol, trehalose, glycine, sodium chloride, dextran and glucose.
  • the isotonic agents may be used in quantities which impart to the formulation the same osmotic pressure as body fluid.
  • the precise amount necessary to achieve the desired effect may depend on factors such as the concentration of active agent in the formulation, and is a matter of routine experimentation which the skilled person may determine without exercising any inventive thought and using only common general knowledge. Selection of the isotonic agent is preferably made having regard to the properties, e.g. stability of the active agent.
  • the pH of the formulation of the present invention is typically maintained in the range of about 4 to 10, or more preferably in the range of about 6 to 9.5.
  • the pH is at least about 9.0.
  • the pH is about 9.0 to about 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7 or 9.8.
  • the pH is about 9.1 to about 9.2, 9.3, 9.4, 9.5, 9.6, 9.7 or 9.8.
  • the pH is about 9.2 to about 9.2, 9.3, 9.4, 9.5, 9.6, 9.7 or 9.8.
  • the pH of the liquid or lyophilized pharmaceutical formulation is about 9.0 to about 9.5.
  • the pH of the liquid or lyophilized pharmaceutical formulation is about 9.1 to about 9.4.
  • the pH of the liquid or lyophilized pharmaceutical formulation is about 9.3.
  • the liquid (or in some instances the lyophilized) pharmaceutical formulation comprises a cosolvent.
  • a nonvolatile cosolvent refers to a substance having a vapor pressure lower than 0.50 mm Hg at 25 °C. The purpose of the nonvolatile cosolvent is to facilitate the dissolution of a poorly water-soluble therapeutic compound in water in order to form a solution.
  • nonvolatile cosolvent examples include, without limitation, alkylene glycols such as, liquid PEG MW200-800, propylene glycol, polyhydric alcohols, e.g., mannitol, sorbitol and xylitol; polyoxyethylenes; linear polyols, e.g., ethylene glycol, 1,6-hexanediol, neopentyl glycol and
  • the cosolvent is selected from the group consisting of propylene glycol and ethanol.
  • Formulations according to the invention may contain other excipients commonly employed in injectable formulations in order to provide the required stability and therapeutic efficacy.
  • Excipients may include EDTA as chelating agent or antioxidants such as, e.g., alpha-tocopherol, BHT, BHA and any other excipients commonly used in the preparation of injectable formulations.
  • Antioxidants may be selected from any of those compounds known in the art. The amount of other suitable excipients employed can be determined using only routine experimentation.
  • the term "bulking agent” refers to an ingredient that provides bulk to the pharmaceutical composition.
  • bulking agents include, without limitation, mannitol, trehalose, lactose, sucrose, polyvinyl pyrrolidone, sucrose, glucose, glycine, cyclodextrins, dextran, solid PEGs and derivatives and mixtures thereof.
  • a particularly useful bulking agent in accordance with the present invention is mannitol.
  • Mannitol for instance may be used as isotonic agent, but may also act as bulking agent for lyophilization.
  • Surfactants can also be optionally used in the pharmaceutical composition.
  • surfactants include fatty acid and alkyl sulfonates; benzethanium chloride, e.g., HY AMINE 1622 from Lonza, Inc. (Fairlawn, N.J.); polyoxyethylene sorbitan fatty acid esters, e.g., the TWEEN Series from Uniqema (Wilmington, Del); and natural surfactants, such as sodium taurocholic acid, l-palmitoyl-2-Sn-glycero-3-phosphocholine, lecithin and other phospholipids.
  • Such surfactants e.g., minimize aggregation of lyophilized particles during reconstitution of the product.
  • These surfactants may comprise from about 0.001% to about 5% w/v.
  • the formulation further may comprise pH adjusting agents or buffering agents.
  • the pH adjusting agents or buffering agents of the compositions described herein are capable of raising the pH of the hydrated formulation to typically about 9.0 - 10.0, irrespective of the starting pH of media. In this way, the pH adjusting agents help increase the solubility of the active as pH increases up to pH 10 in a hydrated media to enhance the product release/dissolution profile from the hydrated formulation.
  • pH adjusting agents or buffering agents may be used with the actives and excipients of the present invention
  • acidic agents can also be used to adjust the pH of the pH adjusting agents or buffering agents as long as the pH adjusting agents or buffering agents as a whole raises the pH of the environment for these compounds in the hydrated formulation to greater than about the pKa of the active acid.
  • Suitable pH adjusting agents or buffering agents include, but are not limited to, organic and inorganic basic compounds of a wide range of aqueous solubilities and molecular weights and the like and mixtures thereof.
  • inorganic basic salts include ammonium hydroxide, alkali metal salts, alkaline earth metal salts such as magnesium oxide, magnesium hydroxide, calcium hydroxide, sodium hydroxide, potassium hydroxide, aluminum hydroxide, potassium carbonate, sodium bicarbonate and the like and mixtures thereof.
  • the solubility and the molecular size of the pH adjusting agent may affect its diffusion rate in the hydrated product and influence the dissolution profile of the active agent.
  • the pH adjusting agents or buffering agents are selected from the group consisting of glycine sodium and sodium hydroxide.
  • Other commonly used buffer types for pH 7-10 include, but are not limited to glycine, sodium bicarbonate, tris, borax, diethanolamine, glutamic acid, triethanolamine and the like.
  • the pH adjusting agents or buffering agent is present in a concentration of about 1 mM to about 50 mM. In another group of embodiments, the pH adjusting agents or buffering agent is present in a concentration of about 5 mM to about 10 mM. In one group of embodiments, the pH adjusting agent is glycine present in a
  • the pH adjusting agent is glycine present in a concentration of about ImM to 50mM; or 5 mM to 10 mM.
  • the invention provides a liquid or lyophilized composition wherein amount of pH adjusting agents or buffering agent is from about 1 to about 20 percent of the total composition. In one aspect, the invention provides a liquid or lyophilized composition wherein the combined percent of the pH adjusting agents or buffering agent is greater than or equal to the percent of the active. In one aspect, the invention provides a liquid or lyophilized composition wherein the amount of pH adjusting agents or buffering agent is from about 2 to about 15 %. In one aspect, the invention provides a liquid or lyophilized composition wherein said composition comprises from about 3 % to about 10 % of the total composition.
  • Water is weighed and added to a stainless steel vessel. Glycine and mannitol are added and mixed to dissolve.
  • the Active Agent is added and mixed to dissolve.
  • the active ingredient is Elinogrel sodium. pH is adjusted to final pH by addition of a solution of NaOH.
  • a pre-filtration is conducted, followed by a sterile filtration before the liquid being filled in glass vials and lyophilized.
  • the lyophilization process starts with a freezing step, followed by a primary drying step under vacuum to remove the ice formed during freezing. In the last step of the lyophilization process, the secondary drying, any residual amounts of liquid which could not be removed by sublimation are removed under vacuum near or above ambient temperature to obtain a stable cake which can dissolve readily.
  • a process of preparing a formulation according to the present invention comprises the step of adding or admixing an aqueous solution, e.g. a isotonic solution, to a compound and mannitol and optionally other pharmaceutically acceptable excipients such as e.g. an antioxidant, in a suitable vessel from a material which is non-reactive or substantially non-reactive with the formulation.
  • an aqueous solution e.g. a isotonic solution
  • a compound and mannitol and optionally other pharmaceutically acceptable excipients such as e.g. an antioxidant
  • the formulation is lyophilized.
  • Lyophilization or more commonly known as “freeze-drying" is a process which extracts water from a solution to form a granular solid or powder. The process is carried out by freezing the solution and subsequently extracting any water or moisture by sublimation under vacuum. Lyophilization is particularly useful for developing pharmaceutical drug products that are reconstituted and administered to a patient by injection, for example drug products.
  • the compound is lyophilized in the presence of a bulking agent and/or a non-volatile co-solvent to a pharmaceutically acceptable cake.
  • compositions and dosage forms are known or will be apparent to those skilled in the art.
  • a liquid or lyophilized dosage form of the present invention can be prepared according to the procedures set forth, for example, in Remington: The Science and Practice of Pharmacy, 20 m Ed., Lippincott,
  • an appropriate amount e.g., conveniently a therapeutically effective amount of the compound is mixed with a water or an aqueous-based solvent, a nonvolatile cosolvent (optional) and a bulking agent to form a solution.
  • the solution contains, e.g., a concentration of the bulking agent from about 0.1% to about 60%> (w/v), e.g., 1% to about 50%> or about 1% to 10% or about 3 to 5%, e.g. about 4%.
  • the formulation comprises about 40 mg/ml of the bulking agent.
  • suitable bulking agents have been described above.
  • a preferred bulking agent in accordance with the present invention is mannitol. In one embodiment, the mannitol is D(-)mannitol.
  • the solution optionally contains, e.g., a concentration of the nonvolatile cosolvent from about 0.01% to about 75% (w/v), e.g., about 0.1 % to about 50% or about 50% to about 75%, e.g., about 1% to about 25% or about 25% to about 75%.
  • a concentration of the nonvolatile cosolvent from about 0.01% to about 75% (w/v), e.g., about 0.1 % to about 50% or about 50% to about 75%, e.g., about 1% to about 25% or about 25% to about 75%.
  • a surfactant can also be added.
  • the resulting solution is typically homogeneous and optically clear.
  • the solution does not comprise any solvents having a relatively high vapor pressure, e.g. lower alcohols, such as ethanol, isopropanol or tert-butanol.
  • the concentration of the compound in the solution is preferably at least 3 mg/ml, preferably at least 4 mg/ml, more preferably at least 15 mg/ml.
  • the concentration of the compound is between 4 mg/ml and 25 mg/ml, e.g. between 15 mg/ml and 23 mg/ml.
  • the solution before lyophilization contains 4 mg/ml to 25 mg/ml such as, e.g., 10 mg/ml to 15 mg/ml or e.g., 15 mg/ml to 23 mg/ml of compound (free base equivalent) in 1% to 10% such as, e.g., 3% to 5% mannitol, or e.g. 4%.
  • additional excipients such as e.g. nonvolatile cosolvent or a surfactant present, in one preferred embodiment, the solution does not contain additional excipients.
  • the solution is filled into a container that is suitable for lyophilization, e.g., a glass vial.
  • the lyophilization cycle typically includes the following steps: a freezing step, a primary drying step and a secondary drying step.
  • the freezing step the solution is cooled.
  • the temperature and duration of the freezing step is chosen such that all of the ingredients in the composition are completely frozen.
  • a suitable freezing temperature is approximately -40°C.
  • the water in the formulation becomes crystalline ice.
  • the balance of the formulation in the frozen state may be crystalline, amorphous or a combination thereof.
  • the primary drying step the ice formed during freezing is removed by sublimation at sub-ambient temperatures under vacuum.
  • the chamber pressure used for sublimation can be from about 40 milliTorr to 400 milliTorr and the temperature be between -30 °C to -5 °C.
  • the formulation should be maintained in the solid state below the collapse temperature ("T c ") of the formulation.
  • T c is the temperature above which the freeze-dried -cake loses macroscopic structure and collapses during freeze-drying.
  • T g glass transition temperature
  • T e eutectic temperature
  • T g for the maximally freeze concentrated solution (“T' g ”) is important to the development of lyophilization cycles because this represents the highest temperature that is safe for the composition for primary drying.
  • T' g maximally freeze concentrated solution
  • any residual amounts of liquid which could not be removed by sublimation is removed by secondary drying, i.e., desorption.
  • the temperature during secondary drying is near or greater than ambient temperature.
  • the pharmaceutical composition becomes a cake.
  • Such a cake should be pharmaceutically acceptable.
  • a "pharmaceutically acceptable cake” refers to a non-collapsed solid drug product remaining after lyophilization that has certain desirable characteristics, e.g.
  • the pharmaceutically acceptable cake can be solid, powder or granular material.
  • the pharmaceutically acceptable cake may also contain up to five percent water by weight of the cake.
  • the bulking agent will not sublime from the pharmaceutical composition.
  • the cake e.g. comprises from about 0.1% to about 60%> (w/w) of the bulking agent; e.g., from about 1% to about 50%) (w/w); e.g., from about 1% to about 10% (w/w).
  • Suitable bulking agents has been described above.
  • the cake conveniently comprises of the mannitol from about 1% to about 10% (w/w), e.g., from about 3% to about 5% (w/w), e.g., from about 4% (w/w).
  • the pharmaceutical composition or pharmaceutically acceptable cake will suitably contain between 0.1 mg and 250 mg of the therapeutic compound per unit dose, e.g., 0.1 mg, 1 mg, 5 mg, 10 mg, 15 mg, 17 mg, 20 mg, 23 mg, 25 mg, 50 mg, 100 mg, 120 mg, or 150 mg per unit dose. In some embodiments 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 or 120 mg per unit dose is used.
  • a "lyophilized pharmaceutical composition” refers to a non-collapsed solid drug product remaining after lyophilization that has certain desirable characteristics, e.g., pharmaceutically acceptable, long-term stability, a short reconstitution time, an elegant appearance and maintenance of the characteristics of the original solution upon reconstitution.
  • the lyophilized pharmaceutical composition can be solid, powder or granular material.
  • the lyophilized pharmaceutical composition may also contain up to five percent water by weight of the cake.
  • the lyophilized pharmaceutical composition cake can be reconstituted, e.g., for instant use. If all required components (e.g., buffer, isotonic agent) are present in the cake, sterile de-ionized water may be used for the reconstitution. Alternatively, an isotonic solution such as e.g. PLASMA-LYTE A® from Baxter or Ringer Acetate Solution from Baxter may be used for reconstitution.
  • the reconstituted solution typically contains about 4 mg/ml to about 25 mg/ml such as, e.g., 15 mg/ml to 23 mg/ml of compound (free acid equivalent).
  • the reconstituted solution contains at least 3 mg/ml, at least 4 mg/ml or at least 15 mg/ml of compound.
  • the reconstituted solution typically contains 1% to 50%, e.g., 1% to 10%, e.g., 3%) to 5% of mannitol.
  • the pH of the reconstituted solution is between 4 to 10, e.g., preferably 9 to 10, e.g. about 9.0 to about 9.5.
  • the pH is about 9.0 to about 9.1 , 9.2, 9.3, 9.4, 9.5, 9.6, 9.7 or 9.8. In one embodiment, the pH is about 9.1 to about 9.2, 9.3, 9.4, 9.5, 9.6, 9.7 or 9.8. In one embodiment, the pH is about 9.2 to about 9.2, 9.3, 9.4, 9.5, 9.6, 9.7 or 9.8. In another group of embodiments, the pH of the liquid or lyophilized pharmaceutical formulation is about 9.0 to about 9.5. In one embodiment the pH of the liquid or lyophilized pharmaceutical formulation is about 9.1 to about 9.4. In one embodiment the pH of the liquid or lyophilized pharmaceutical formulation is about 9.3.
  • the dosage form to be administered will, in any event, contain a quantity of the therapeutic agent in a therapeutically effective amount for relief of the condition being treated when administered in accordance with the teachings of this invention.
  • the compositions of the present invention comprise at least about 3 mg/mL by weight of the active agent (in whatever chosen form, measured as per its free acid form), and more typically from about 4 mg/mL to about 25 mg/mL. In some embodiments, about 10 mg/mL to about 15 mg/mL, or about 15 mg/mL to about 23 mg/mL of the active agent is used.
  • the formulation is not refrigerated and can be stored and used at room temperature. In other embodiments, the formulation can be refrigerated.
  • the dose and method of administration will vary from subject to subject and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concurrent medication, overall clinical condition, the specific use for which the compound or pharmaceutical composition is employed, and other factors which those skilled in the medical arts will recognize.
  • compositions of the present invention are useful in therapeutic applications, e.g., for treating thrombosis.
  • the compositions of the present invention offer advantages over compositions for injectable administration that do not contain an excipient described herein.
  • the excipient, co-solvent, pH adjusting agent or buffering agent or combination thereof in the compositions of the present invention can help increase the solubility of the active, the therapeutic agent can be administered with a higher dosage form and a larger amount of the therapeutic agent can be in systemic circulation in a substantially shorter period of time ⁇ e.g., reducing the time to onset of therapeutic activity) and at a substantially higher concentration than with compositions for injectable
  • compositions of the present invention have particular utility in the area of human and veterinary therapeutics.
  • the compositions of the present invention may be administered to deliver an active agent to any animal in need thereof, including, but not limited to, mammals, such as rodents, cows, pigs, dogs, cats, and primates, particularly humans.
  • administered dosages will be effective to deliver picomolar to micromolar concentrations of the active agent to the appropriate site.
  • Administration of the compositions of the present invention is preferably carried out via any of the accepted modes of injectable administration.
  • the liquid or lyophilized pharmaceutical formulation is administrable by intravenous (bolus and/or infusion), perivascular, subcutaneous, intramuscular, parenteral or intraperitoneal injection.
  • the formulation is suitable for intravenous
  • compositions of the invention are suitable for use alone or as part of a multi-component treatment regimen for the prevention or treatment of cardiovascular diseases, particularly those related to thrombosis.
  • a compound or pharmaceutical composition of the invention may be used as a drug or therapeutic agent for any thrombosis, particularly a platelet-dependent thrombotic indication, including, but not limited to, acute coronary syndrome, ACS, acute myocardial infarction, unstable angina, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, preeclampsia/eclampsia, deep venous thrombosis, embolism, disseminated intravascular coagulation and thrombotic cytopenic purpura, thrombotic and restenotic complications following invasive procedures, e.g., angioplasty, carotid endarterectomy, post CABG (coronary artery bypass graft) surgery, vascular graft surgery, stent placements and insertion of endovascular devices and protheses, and hypercoagulable states related to genetic predisposition or cancers.
  • a platelet-dependent thrombotic indication including, but not limited to, acute coronary
  • the indication is selected from the group consisting of percutaneous coronary intervention (PCI) including angioplasty and/or stent , acute myocardial infarction (AMI), unstable angina (USA), coronary artery disease (CAD), transient ischemic attacks (TIA), stroke, peripheral vascular disease (PVD),
  • PCI percutaneous coronary intervention
  • AMI acute myocardial infarction
  • CAD coronary artery disease
  • TIA transient ischemic attacks
  • stroke peripheral vascular disease
  • compositions of the invention may also be used as part of a multi- component treatment regimen in combination with other therapeutic or diagnostic agents in the prevention or treatment of thrombosis in a mammal.
  • compounds or pharmaceutical compositions of the invention may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice such as anticoagulant agents, thrombolytic agents, or other antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, heparin, enoxaparin, glycoprotein (GP) 2b/3a inhibitors, aspirin, statins, angiotensin-converting enzyme (ACE) inhibitors or warfarin or anti-inflammatories (non-steriodal anti-inflammatories, cyclooxygenase II inhibitors).
  • Coadministration may also allow for application of reduced doses of both the anti-platelet and the thrombo
  • Compounds and pharmaceutical compositions of the invention may also act in a synergistic fashion to prevent reocclusion following a successful thrombolytic therapy and/or reduce the time to reperfusion.
  • compositions of the invention may be administered by injection in an effective amount within the dosage ranges described herein in a regimen of single or multiple (twice, etc.) daily or single or multiple weekly doses.
  • compositions of the invention may be utilized in vivo, ordinarily in mammals such as primates, (e.g., humans), sheep, horses, cattle, pigs, dogs, cats, rats and mice, or in vitro.
  • mammals such as primates, (e.g., humans), sheep, horses, cattle, pigs, dogs, cats, rats and mice, or in vitro.
  • the biological properties, as defined above, of a pharmaceutical composition of the invention can be readily characterized by methods that are well known in the art such as, for example, by in vivo studies to evaluate antithrombotic efficacy, and effects on hemostasis and hematological parameters.
  • compositions of the invention may be indicated in standard
  • compositions of the invention lead to an inter- and intra-patient reduced variability of Elinogrel, Elinogrel salt, for example potassium Elinogrel, or Elinogrel sodium.
  • compositions of the invention are particularly useful for treatment or prevention of ADP -mediated disease or condition.
  • ADP -mediated disease or condition refers to a disease or condition characterized by less than or greater than normal, ADP activity.
  • An ADP -mediated disease or condition is one in which modulation of ADP results in some effect on the underlying condition or disease (e.g., a ADP inhibitor or antagonist results in some improvement in patient well-being in at least some patients).
  • compositions of the invention are useful for the treatment and prevention of acute coronary syndrome or in secondary prevention thereof.
  • the dose of the Elinogrel, Elinogrel salt, e.g. sodium Elinogrel salt, or Elinogrel crystalline or amorphous form may vary depending on a variety of factors, for example the compound chosen, the particular condition to be treated and the desired effect. Dosages of Elinogrel salt or polymorph are to be calculated to correspond to the above mentioned dosages of Elinogrel free acid.
  • co-administration or “combined administration” or the like as utilized herein are meant to encompass administration of the drug substance to a single patient, and are intended to include treatment regimens in which the agents are not necessarily
  • the term "pharmaceutical combination” as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients.
  • the term "fixed combination” means that the drug substance and the active co-agent are both administered to a patient simultaneously in the form of a single entity or dosage.
  • the term “non-fixed combination” means that the active ingredients, e.g. a compound of formula I and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient.
  • cocktail therapy e.g. the administration of 3 or more active ingredients.
  • standard clinical study comprises the conduct of such a study as regulated by health authorities e.g. Guidance for Industry, Bioavailability and
  • Still another aspect of this invention is to provide a kit comprising a container in a single package, wherein the inventive pharmaceutical compositions thereof are used alone or in combination with pharmaceutically acceptable carriers to treat states, disorders, symptoms and diseases.
  • the resultant formulation may be maintained under an inert atmosphere and is transferred to suitable containers, e.g. by a cannular system also under the inert atmosphere.
  • Solvents other than water, when required, and other reagents may be chosen from medical grade reagents and solvents well known in the art.
  • Formulations according to the invention may be packaged in containers. Containers may be chosen which are made of material. Glass containers may be used although it is preferred to use plastic containers, e.g. plastic infusion bags.
  • the invention provides an article of manufacture comprising a container enclosing a formulation disclosed herein.
  • the article of manufacture is a pre-filled syringe.
  • the pre-filled syringe is further contained within an injection device.
  • the injection device is an auto-injector.
  • a single dosage form suitable for e.g. intravenous administration comprising an effective amount of the compound and, optionally, further excipients commonly used in pharmaceutical compositions as e.g. described hereinabove.
  • the single dosage form contains at least 3 mg/ml, preferably at least 4 mg/ml more preferably at least 15 mg/ml of the compound.
  • Example 1 Aqueous solubilities of Elinogrel as various salt forms and as a function of pH.
  • Table 1 Kinetic solubility of Forms B & C of Elinogrel potassium in a liquid formulation containing mannitol and glycine buffer.
  • thermodynamic solubility of Elinogrel potassium salt and free acid in pH range of 1-10 at 37°C was also determined.
  • Excess Elinogrel free acid or potassium salt (start from Form B) was equilibrated with its aqueous slurries at various pH under constant agitation. Different amounts of NaOH or HCl solution were used to adjust pH. Solubility was determined after 3 days by analyzing the elinogrel concentration in supernatant of the slurry after ultracentrifugation. Results were shown in Figure 2 and Tables 2 and 3.
  • thermodynamic solubility of Elinogrel as a potassium salt at different pH adjusting pH with either NaOH or HCl at 37°C.
  • thermodynamic solubility of Elinogrel as a free acid at different pH adjusting pH with either NaOH or HC1 at 37°C.
  • Example 2 Elinogrel potassium solubilities in sodium sulfobutyl ether ⁇ -cyclodextrin
  • Elinogrel potassium (Form C) solubility is 11.5 mg/mL in 20% sodium sulfobutyl ether ⁇ -cyclodextrin, which is approximately 4-fold as that in water. Therefore, sodium sulfobutyl ether ⁇ -cyclodextrin is able to increase Elinogrel potassium solubility by complexation.
  • Elinogrel sodium hydrate was prepared by recrystallization from supersaturated elinogrel sodium solution in 5% sodium sulfobutyl ether ⁇ -cyclodextrin when stored at 4°C overnight. The white to off-white wet solids were collected by centrifugation at 13,000 rpm for 5 min and supernatant removal. Based on DSC and polarized light microscopy, Elinogrel sodium hydrate lost water upon air-dry and converts to amorphous.
  • Elinogrel sodium hydrate solubilities in different vehicles are summarized in Table 7.
  • Elinogrel sodium solubility is approximately 9-fold of that of Elinogrel potassium in water. Its solubility in sodium glycine buffer is slightly lower than that in water, likely due to a common-ion effect (Na).
  • Example 6 Dissolution studies using Elinogrel potassium, Elinogrel free acid (to form in-situ sodium salt) or Elinogrel sodium as starting material
  • Dissolution time for forming in-situ sodium salt using Elinogrel free acid as a starting material was performed in 50 mM Glycine and 4% mannitol (pH 9.0, 9.3 and 9.5) at 50°C to have a final concentration of 20 mg/mL as of free acid and final volume 250 mL.
  • Exact amount of NaOH in IN solution was added for Elinogrel free acid conversion to Elinogrel sodium. If solids did not completely dissolve at 50°C in 6 hours, then excess amount of NaOH was added to increase pH to expedite dissolution.
  • Around 1 mL scale experiments at pH range 9.5 to 10.0 (target concentration 15 mg/mL) were set up and dissolution time at ambient and 50°C was recorded.
  • Elinogrel sodium could also be formed in situ from elinogrel free acid at higher pHs. Suspension at pH 9.0 was added with extra NaOH to increase the pH to 10.3 and solids were dissolved in 1 hour. IN HC1 was then used to adjust pH back to 9.0. The resulted solution was stored at 25°C overnight and needle/blade-shaped crystals precipitated overnight. It is considered that the precipitates are Elinogrel sodium hydrate and its concentration was reduced to 6 mg/mL. This is possibly due to the common-ion (Na) effect (around 40mM sodium chloride generated during pH adjustment on top of 50mM sodium glycine).
  • Na common-ion
  • a stable Elinogrel sodium solution could be formed in situ from elinogrel free acid at higher pHs.
  • a suspension was added with NaOH to increase the pH to 11.2 and solids were dissolved in 55 minutes, while the pH dropped to 10.
  • the final 15mg/ml Elinogrel solution was obtained containing lOmM of glycine, 4% of mannitol having a pH of 9.2.
  • the resulted solution was stored at room temperature for more than 3 days without precipitation. It was demonstrated that the purity of Elinogrel was not impacted by the pH excursion.
  • Elinogrel sodium dissolution was also performed to have a target concentration of 15 mg/mL (as free acid) and pH 9.3 in 10 mM glycine and 4% mannitol.
  • Elinogrel sodium was dissolved completely in less than 2 min for 50 mL scale with gentle swirl/vortex or less than 60 minutes for up to 140 L scale with impeller agitation at ambient temperature. This approach offers significant advantage due to ease of processing.
  • Example 7 Elinogrel IV lyophilized formulation & process
  • One IV drug formulation comprises a lyophilized powder for reconstitution, 20mg of Elinogrel per vial.
  • the product is reconstituted with 5 mL of water for injection (WFI) within 24 hours prior to dose administration.
  • WFI water for injection
  • the pH was adjusted to 9.0 ⁇ 0.2 using NaOH in bulk solution prior to lyophilization.
  • the glycine sodium is 50mM in bulk solution (prior lyophilization) or post reconstitution.
  • the process for making the solution is outlined below.
  • About 88% WFI is weighed and added to a stainless steel or glass pot, and heated to ⁇ 45°C. The temperature is maintained below 45°C.
  • Glycine is added and mixed to dissolve.
  • Mannitol is added and mixed to dissolve. pH is adjusted to 9.0 ⁇ 0.2 with IN NaOH or HC1. Compound is added and mixed to dissolve while heating the bulk solution (40-45°C). The pH is confirmed and adjusted to 9.0 ⁇ 0.2 if necessary. Heating is discontinued.
  • QS is targeted with WFI.
  • the final theoretical concentration of Elinogrel in bulk solution is 4mg/ml (as of free acid equivalent). A bioburden sample is obtained.
  • Pre-filtration is conducted (0.45 ⁇ followed by 0.22 ⁇ ), and the bulk solution is held overnight if required by manufacturing schedule.
  • the solution is double sterile filtered (double 0.22 ⁇ ) before being lyophilized.
  • the lyophilization process is composed of commonly adopted procedure that involves freezing, primary drying, and secondary drying.
  • Example 8 Elinogrel IV lyophilized formulation & process
  • One IV drug formulation comprises a lyophilized powder for reconstitution, 80mg of Elinogrel per vial.
  • the product is reconstituted with 8 mL of WFI within 24 hours prior to dose administration.
  • Each vial (before lyophilization) contains the following: Component mg/mL mg/vial 1
  • the pH was adjusted to 9.3 using NaOH in bulk solution prior to lyophilization.
  • the glycine sodium is lOmM in bulk solution (prior lyophilization) and post reconstitution.
  • composition refers to the nominal volume of 8.0 mL, the overfill of 0.4 ml is not considered.
  • the process for making the solution is outlined below. About 85% WFI is weighed and added to a stainless steel vessel at ambient temperature. Glycine is added and mixed to dissolve. Mannitol is added and mixed to dissolve. pH is adjusted to 9.0 ⁇ 0.1 with IN NaOH. Compound is added and mixed to dissolve. pH is adjusted to 9.3 ⁇ 0.1. The final theoretical concentration of Elinogrel in bulk solution is 15mg/ml (as of free acid equivalent). Pre-filtration is conducted using a 0.2 ⁇ rated Supor EAV polyethersulfone filter, followed by a double sterile filtration (0.22 ⁇ twice) before being filled in 20R glass vials and lyophilized. The lyophilization process is composed of a procedure that involves freezing, primary drying, and secondary drying.
  • the shelves are cooled down to -19°C at a rate of 0.6 °C/min and held for 3 hours at -19°C. Then the shelves are cooled down to -40°C at a speed of l°C/min and kept at -40°C for 3 hours. After two hours at -40°C, the primary drying is started by reducing the pressure to 0.5 mbar and after three hours at -40°C, the temperature is raised to 0°C at a speed of 1 °C/min and kept for 30H at 0°C for the rest of the primary drying.
  • One IV drug formulation comprises a lyophilized powder for reconstitution, 120mg of Elinogrel per vial.
  • the product is reconstituted with 8 mL of WFI within 24 hours prior to dose administration.
  • Each vial (before lyophilization) contains the following:
  • the pH was adjusted to 9.3 using NaOH in bulk solution prior to lyophilization.
  • the glycine sodium is 1 OmM in bulk solution prior lyophilization and post reconstitution.
  • composition refers to the nominal volume of 8.0 mL, the overfill of 0.4 ml is not considered.
  • IV Intravenous
  • Injection sites were observed at 1, 3, and 6 hours post-injection and then twice a day for 5 days. On day 5, tissues (ears and skin) were harvested and processed for histological examination of the injection site.
  • the intravenous, perivascular and subcutaneous administration of Elinogrel at 4.0 or 16.7 mg/mL yielded similar animal observation as the vehicle and saline control and the formulations were well tolerated.
  • Example 11 Clinical testing of elinogrel potassium formulation
  • the elinogrel potassium IV formulation has been tested in multiple clinical studies (06-106, 07-112, and 07-113), total >100 subjects.
  • the tested doses are in the range of lOmg to 60mg per subject.
  • the doses were administered either as 20min i.v. infusion or i.v. bolus. All tested doses have been well tolerated. There have been no deaths, 2 SAEs (vs. 8 SAEs in the placebo comparator arm), and 1 discontinuation due to a mild adverse event associated with iv elinogrel administration.
  • the elinogrel sodium IV formulation according to Example 9 has been tested in clinical studies in humans.
  • the tested dose was 60mg per subject, administered as an i.v. bolus dose.
  • the intravenous administration of 60 mg Elinogrel gave a rapid onset of P2Y12 inhibition measured using VerifyNow cartridges with obtained peak P2Y12 inhibition within one hour after administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une forme liquide d'administration de l'élinogrel pour le traitement de la thrombose qui est remarquable pour l'amélioration de ses propriétés galéniques et de sa stabilité. La forme galénique est une forme liquide ou lyophilisée qui est reconstituée pour une formulation injectable, comprenant : a) au moins environ 3 mg/ml ou jusqu'à environ 15 mg/ml d'élinogrel ou de l'un de ses sels pharmaceutiquement acceptables (après reconstitution ou sous forme liquide) et b) au moins un excipient pharmaceutiquement acceptable. D'autres aspects de la présente invention concernent la préparation et l'utilisation d'une telle formulation.
PCT/US2011/034861 2010-04-30 2011-05-02 Formes galéniques de l'élinogrel et leurs méthodes d'administration injectables WO2011137459A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/695,428 US20130131089A1 (en) 2010-04-30 2011-05-02 Dosage forms of elinogrel and methods of injectable administration thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32972510P 2010-04-30 2010-04-30
US61/329,725 2010-04-30

Publications (1)

Publication Number Publication Date
WO2011137459A1 true WO2011137459A1 (fr) 2011-11-03

Family

ID=44129257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/034861 WO2011137459A1 (fr) 2010-04-30 2011-05-02 Formes galéniques de l'élinogrel et leurs méthodes d'administration injectables

Country Status (1)

Country Link
WO (1) WO2011137459A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018167139A1 (fr) * 2017-03-15 2018-09-20 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070123547A1 (en) 2005-11-03 2007-05-31 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
WO2008137753A2 (fr) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Dosage oral et intraveineux de l'inhibiteur p2y12 réversible et à action directe
WO2008137809A2 (fr) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Sels de [4(-(6-fluoro-7-méthylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phényl]-5-chloro-thiophén-2-yl-sulfonylurée, formes et procédés qui leur sont associés

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070123547A1 (en) 2005-11-03 2007-05-31 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
WO2008137753A2 (fr) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Dosage oral et intraveineux de l'inhibiteur p2y12 réversible et à action directe
WO2008137809A2 (fr) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Sels de [4(-(6-fluoro-7-méthylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phényl]-5-chloro-thiophén-2-yl-sulfonylurée, formes et procédés qui leur sont associés
US20090042916A1 (en) 2007-05-02 2009-02-12 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Guidance for Industry, Bioavailability and Biocquivalcncc, Studies for Orally Administered Drug Products - General Considerations", March 2003, CENTER FOR DRUG EVALUATION AND RESEARCH, FOOD AND DRUG ADMINISTRATION
"Pharmaceutical Dosage Forms, Volume 1: Tablets", 1989, MARCEL DEKKER, INC.
"Remington: The Science and Practice of Phannacy", 2003, LIPPINCOTT, WILLIAMS & WILKINS
BERGER J S ET AL: "Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intra", AMERICAN HEART JOURNAL, MOSBY- YEAR BOOK INC, US, vol. 158, no. 6, 1 December 2009 (2009-12-01), pages 998 - 1004.E1, XP026787889, ISSN: 0002-8703, [retrieved on 20091201], DOI: DOI:10.1016/J.AHJ.2009.10.010 *
JOLANTA M SILLER-MATULA ET AL: "Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases", BRITISH JOURNAL OF PHARMACOLOGY, vol. 159, no. 3, 24 December 2009 (2009-12-24), pages 502 - 517, XP055000891, ISSN: 0007-1188, DOI: 10.1111/j.1476-5381.2009.00555.x *
MEINER, TONASCIA: "Clinical Trials: Design, Conduct, and Analysis", MONOGRAPHS IN EPIDEMIOLOGY AND BIOSTATISTICS, vol. 8, 1986

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018167139A1 (fr) * 2017-03-15 2018-09-20 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
KR20190124297A (ko) * 2017-03-15 2019-11-04 이도르시아 파마슈티컬스 리미티드 P2y12 수용체 안타고니스트의 피하 투여
JP2020510043A (ja) * 2017-03-15 2020-04-02 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｙ１２受容体アンタゴニストの皮下投与
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
KR102510832B1 (ko) * 2017-03-15 2023-03-15 이도르시아 파마슈티컬스 리미티드 P2y12 수용체 안타고니스트의 피하 투여

Similar Documents

Publication Publication Date Title
JP4077794B2 (ja) 抗新生物薬剤、特にテモゾロミドの薬学的処方物、その同一物の製造方法および使用方法
CA2234140C (fr) Formulation pharmaceutique lyophilisee stable
BR112019018420A2 (pt) composição farmacêutica que compreende selexipag
WO2007082978A1 (fr) Formulation pharmaceutique de taxane, composition solide de taxane, procédé de préparation de la composition solide de taxane, composition solubilisant de la composition solide de taxane et ensemble d'éléments (kit) pour cette formulation
PL201188B1 (pl) Sposób wytwarzania suszonego sublimacyjnie preparatu zawierającego 5-difluorometoksy-2-[(3,4-dimetoksy-2-pirydynylo)metylosulfinylo]-1H-benzimidazol (pantoprazol), jego sól, solwat pantoprazolu lub jego sól, liofilizowany preparat pantoprazolu otrzymany tym sposobem, preparat do iniekcji oraz zestaw zawierający preparat liofilizowany
ES2719348T3 (es) Composición farmacéutica estable de alta resistencia de levoleucovorina
US10039780B2 (en) Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
KR101777587B1 (ko) 주사가능한 이부프로펜 제제
JP2018528242A (ja) 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法
JP2005533056A (ja) 非経口抗真菌生成物
JP2022003101A (ja) 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2007500191A (ja) Ｃｃｉ−７７９の凍結乾燥処方
AU2017364135A1 (en) Pharmaceutical parenteral formulation containing carglumic acid
JP2011137048A (ja) 新たな用途の薬学的調製物およびその調製物を製造するためのプロセス
US20130131089A1 (en) Dosage forms of elinogrel and methods of injectable administration thereof
WO2011137459A1 (fr) Formes galéniques de l'élinogrel et leurs méthodes d'administration injectables
JP2023536509A (ja) アクアポリン阻害剤の医薬組成物およびその製造方法
JP2023516957A (ja) ダプトマイシン製剤
WO2022115179A1 (fr) Compositions comprenant une protéine de tnf négative dominante et procédés d'administration thérapeutique
WO2011101865A2 (fr) Compositions pharmaceutiques stables de clopidogrel pour administration parentérale
CZ20003208A3 (cs) Farmaceutické přípravky obsahující inhibitor fosfolipázy [[3-(2-amino-l,2-dioxoethyl)-2-ethyll-(fenylmethyl)-lH-indol-4-yl]oxy]acetát sodný

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11717923

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13695428

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 11717923

Country of ref document: EP

Kind code of ref document: A1